Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

PSFE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Paysafe Limited (PSFE) Investors of Securities Class Action Deadline on April 7, 2026

March 3, 2026

MycoTechnology’s Honey Truffle Sweet Protein Achieves Regulatory Milestone, Enters U.S. Market at Commercial Scale

March 3, 2026

AI Disruption Global Overview Report 2026: AI-Driven Capital Reallocation, Job Market Restructuring and Ecosystem Consolidation Signal Profound Structural Transformation

March 3, 2026

EverWind lands more than $240M in financing for N.S. wind and hydrogen projects

March 3, 2026

Anti-Migrating Agent Market Research and Global Forecast Report 2026-2035: $1.34 Bn Growth Opportunities Driven by Demand in Textiles, Plastics, Coatings, and Printing Sectors

March 3, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » ‘Patients get relief’: Researchers recommending nerve blockers to treat migraines
Health

‘Patients get relief’: Researchers recommending nerve blockers to treat migraines

By News RoomDecember 5, 20254 Mins Read
‘Patients get relief’: Researchers recommending nerve blockers to treat migraines
Share
Facebook Twitter LinkedIn Pinterest Email

Calgary neurologist Dr. Serena Orr spent her career researching migraine attacks and trying to bring patients relief from the painful symptoms.

But it wasn’t until she moved to Calgary that she gained a whole new perspective with a migraine attack of her own.

“I had mild headaches in all the other places I lived but didn’t think anything of it. It was during COVID. I couldn’t get off the couch. I had severe nausea and brain fog. When the fog started to fade, I realized I didn’t have COVID. I had experienced a severe migraine attack,” Orr said.

“I didn’t understand how bad it was until I experienced it myself. It is super ironic.”

Orr, an associate professor at the University of Calgary’s Cumming School of Medicine, worked in collaboration with researchers at the University of Calgary’s Hotchkiss Brain Institute and the Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital and Medical Center in Phoenix, Arizona.

The findings are published in “Headache: The Journal of Head and Face Pain” and update the 2016 guidelines of the American Headache Society for the management of migraine attacks in emergency departments.

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.

The update reviewed 26 studies from the past nine years that met the criteria involving migraines and visits to emergency departments to bring the treatment recommendations up to date.

“This update marks a major change in emergency department migraine care and implementing these treatments can improve patient outcomes and reduce reliance on opioids,” said study co-lead Dr. Jennifer Robblee, a neurologist and migraine and headache disorders specialist at Barrow Neurological Institute.


The research recommends occipital nerve blocks should be offered in emergency rooms to treat acute migraine attacks.

The use of intravenous Prochlorperazine which blocks dopamine receptors in the brain is recommended but is not readily available. That leaves the greater occipital nerve block where a local anesthetic and a corticosteroid are injected near the greater occipital nerve.

“The occipital nerves at the base of the skull bring in pain signals to the same area of the brain where pain signals from all over the head are coming in. By anesthetizing these nerves, patients get relief,” said Orr.

“A needle at the back of the head and pushing in a local anesthetic for the nerves to numb the back of the head also changes the pain signaling from all over the head and the brain.”

Orr was lead author on the 2016 guidelines which were adopted in Canada and has reached out to the Canadian Headache Association and other neurologists and emergency room doctors to encourage their implementation.

“They are American Headache Society’s guidelines but now that they’ve been published this week I’m in touch with Canadian organizations,” she said.

“They’re looking at it and are likely to endorse the things on it.”

The study also recommends against using opioids to treat headaches because other treatments are better and because of the possible addiction issues.

Orr said migraines are one of the most common neurological diseases in the world and are largely believed to be genetic, with other factors including childhood trauma or even weather conditions and altitude being aggravating factors.

The needles need to be applied by physicians or nurse practitioners but Orr doesn’t think most patients would mind.

“The extent of the pain and discomfort made me realize on a very personal level that I would do anything to get rid of it including put needles in my head,” she said.

“Does that mean it’s a cure for everybody? No. We don’t have anything for migraines that everybody will respond well to. We know it’s going to help a lot of people due to good quality research.”

This report by The Canadian Press was first published December 5, 2025.

&copy 2025 The Canadian Press

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Colorectal cancer screening should start at age 45, organization says

Cervical cancer is ‘fastest-rising’ form in Canada as doctors urge action

Canadians’ ease of access to primary care depends on where you live: CMA survey

‘We need to act’ on men’s health, minister says as government seeks feedback

Canada’s incoming top doctor says restoring public trust a top priority

More than 1 in 4 patients leaving Winnipeg ERs without being seen: study

Seasonale and Seasonique birth control recalled due to missing pills

YouTube, Roblox say they deleted accounts tied to Tumbler Ridge shooter

Oysters from Stellar Bay Shellfish brand recalled for norovirus risk

Editors Picks

MycoTechnology’s Honey Truffle Sweet Protein Achieves Regulatory Milestone, Enters U.S. Market at Commercial Scale

March 3, 2026

AI Disruption Global Overview Report 2026: AI-Driven Capital Reallocation, Job Market Restructuring and Ecosystem Consolidation Signal Profound Structural Transformation

March 3, 2026

EverWind lands more than $240M in financing for N.S. wind and hydrogen projects

March 3, 2026

Anti-Migrating Agent Market Research and Global Forecast Report 2026-2035: $1.34 Bn Growth Opportunities Driven by Demand in Textiles, Plastics, Coatings, and Printing Sectors

March 3, 2026

Latest News

Pharmaceutical Contract Manufacturing Market Research 2026-2035: Biologics Boom, GLP-1 Momentum and Patent Expiries Drive Strategic Shift Toward Cost-Efficient Contract Manufacturing Partnerships

March 3, 2026

Surfactant Industry Research and Global Forecast Report 2025-2035: Rapid Industrialization, Bio-Based Surfactant Innovation and Enhanced Oil Recovery Technologies Propel Strong Growth

March 3, 2026

OutSolve Welcomes Jason Rodrigues as Vice President of Sales

March 3, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version